Targets for immunomodulation in cardiovascular disease – where are we now?

ISSN： 1479-6678

Source： Future Cardiology, Vol.1, Iss.2, 2005-03, pp. : 177-189

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Microbicides: where are we now and what next?

By McCormack Sheena

HIV Therapy, Vol. 4, Iss. 6, 2010-11 ,pp. : 615-618

Future Medicine

Access to resources Recommend Favorite

Definitions of Metabolic Syndrome: Where are We Now?

Current Vascular Pharmacology, Vol. 4, Iss. 3, 2006-07 ,pp. : 185-197

Bentham Science Publishers

Access to resources Recommend Favorite

Mucosal HIV Vaccines: Where are We Now?

Current HIV Research, Vol. 2, Iss. 1, 2004-01 ,pp. : 1-10

Bentham Science Publishers

Access to resources Recommend Favorite

Can We Change the Natural History of Crohn's Disease with Early Immunomodulation?

Digestive Diseases, Vol. 32, Iss. 4, 2014-06 ,pp. : 345-350

Karger

Access to resources Recommend Favorite

A Review of Intracoronary Abciximab in Percutaneous Coronary Interventions- where are we now and where do we go from here?

Recent Patents on Cardiovascular Drug Discovery, Vol. 8, Iss. 3, 2013-12 ,pp. : 192-196

Bentham Science Publishers

Access to resources Recommend Favorite